Herpes zoster ophthalmicus in two women after Pfizer-BioNTech (BNT162b2) vaccine

J Med Virol. 2022 Mar;94(3):817-818. doi: 10.1002/jmv.27366. Epub 2021 Oct 7.
No abstract available

Publication types

  • Letter

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Female
  • Herpes Zoster Ophthalmicus* / drug therapy
  • Humans
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Vaccines
  • BNT162 Vaccine